GE HealthCare and Mayo Clinic Collaborate on Personalized Radioligand Therapy for Advanced Prostate Cancer: Launching MI-BET Study

July 19, 2026

GE HealthCare USA

Overview

GE HealthCare and Mayo Clinic have initiated the MI-BET study, a collaborative research effort to advance personalized radioligand therapy (RLT) for patients with advanced prostate cancer. This study will integrate imaging data with blood-based biomarkers to assess adaptive treatment approaches, specifically exploring the potential for treatment pauses based on individual disease response. The goal is to move beyond standardized treatment cycles, reducing patient burden and optimizing therapeutic efficacy.

In Depth

Key Findings

GE HealthCare and Mayo Clinic have forged a groundbreaking research collaboration to advance personalized radioligand therapy (RLT) for patients with advanced prostate cancer, launching the ‘MI-BET study.’ This research aims to leverage insights derived from integrated imaging data and blood-based biomarkers to evaluate the effectiveness of an adaptive approach to treatment, allowing for flexible adjustments to the therapeutic regimen based on each patient’s unique disease response. A key focus is to assess the feasibility of pausing RLT in patients who demonstrate confirmed treatment response, thereby optimizing treatment efficiency and enhancing patient quality of life.

Technical & Clinical Details

The MI-BET study focuses on PSMA-targeted RLT, such as Lutetium-177 (177Lu) DOTA-PSMA, employing serial imaging techniques (e.g., PET/CT) combined with analysis of circulating tumor DNA (ctDNA) and other blood-based biomarkers. This comprehensive approach enables real-time monitoring of treatment response, facilitating individualized decisions regarding the continuation, pausing, or re-initiation of therapy, rather than adhering to rigid, standardized treatment cycles. The objective is to mitigate side effects from unnecessary treatment while maximizing therapeutic benefits. This adaptive treatment paradigm also holds potential for reducing patient risk and optimizing treatment costs.

Background & Context

Advanced prostate cancer often presents with limited treatment options and poor prognosis, particularly in metastatic settings. Radioligand therapy, which precisely delivers radiation to cancer cells, has shown promising clinical outcomes. However, current RLT protocols are often administered in fixed cycles. Given the significant variability in disease progression and treatment response among patients, a more personalized therapeutic approach has become increasingly necessary. The collaboration between GE HealthCare’s advanced imaging technologies and Mayo Clinic’s extensive clinical expertise directly addresses this critical unmet medical need.

Strategic Significance & Outlook

The MI-BET study has the potential to revolutionize RLT optimization in advanced prostate cancer. Successful outcomes from this research could establish RLT as a highly precise form of medicine, accelerating the widespread adoption of tailored treatments for individual patients. Furthermore, the concept of this adaptive treatment approach is transferable to other cancer types and therapeutic modalities, contributing significantly to the broader evolution of personalized medicine. In the long term, AI-driven data analytics are expected to further enhance decision-making in these individualized treatment strategies.

Source: https://investor.gehealthcare.com/news-releases/news-release-details/ge-healthcare-and-mayo-clinic-aim-advance-personalized-cancer

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.